Subscribe

Shanghai Kehua Bio-engineering Co., Ltd. (002022.SZ)

CNY5.21 +0.12 (+2.36%)
CN SHZ Healthcare Medical - Specialties
Address Caohejing Hi-Tech Park 200233
Shanghai, SH, CN
CEO Li Ming
Website skhb.com
IPO 2004-07-21
ISIN CNE000001KC9

Explore sections of this company profile

Description

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium. In addition, the company offers molecular diagnostics solutions, including fully automated nucleic acid blood screening laboratory solution and nucleic acid testing and detection kits; automatic multifunctional veterinary analyzer; and mass spectrometry. It exports its products. The company serves healthcare institutions, blood centers, disease control and prevention centers, and research organizations. Its products are used in clinical diagnostics, blood screening, public health, food safety, and scientific research applications. The company was founded in 1981 and is headquartered in Shanghai, China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY5.21 +0.12 (+2.36%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
0.34
Float Shares
407.31M
Free Float %
79.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.18% -3.73% -8.60% -11.87% -19.23% -8.75% -8.91% -50.28% -71.19% -70.06% +228.03%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
5.21
Ratings Trend (MoM) 80% Bullish
Rating 2024-11 Change
Strong Buy 0 0
Buy 4 0
Hold 0 0
Sell 1 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1.70
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Specialties: +8.3%
    -6.6% Q1'26: +1.9% (vs Q1'25)
  • ✗
    EPS growth Medical - Specialties: +10.1%
    -11.8% Q1'26: +5.8% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Medical - Specialties: +51.3%
    -37.4% Q1'26: -31.4% (vs Q1'25)
  • ✗
    EBIT margin Medical - Specialties: +12.6%
    -48.0% Q1'26: -9.0% (vs Q1'25)
  • ✗
    ROIC Medical - Specialties: +6.6%
    -30.2% Q1'26: -4.8% (vs Q1'25)
  • ✗
    Share dilution Medical - Specialties: 0.0%
    +1.9% Q1'26: +0.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×
    -0.76× Q1'26: -5.07× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.41) × ERP
WACC = 87% × Ke + 13% × Kd (5.6%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 5.21
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2022
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana. 		Dec 2031
1 Rev. Ana.
1 EPS Ana.
Revenue
1.16B
est: 1.15B (+0.3%)
1.40B
est: 1.40B (-0.1%)
1.59B
est: 1.57B (+1.8%)
1.99B
est: 2.04B (-2.6%)
2.41B
est: 2.28B (+6.0%)
4.16B
est: 3.21B (+29.5%)
3.31B
est.
4.85B
est: 3.91B (+24.2%)
6.97B
est: 3.91B (+78.4%)
1.64B
est: 1.57B (+4.9%)
1.57B
1.57B – 1.57B
+0.0% YoY
2.04B
2.04B – 2.04B
+30.6% YoY
2.28B
2.28B – 2.28B
+11.4% YoY
3.21B
3.21B – 3.21B
+40.9% YoY
3.31B
3.31B – 3.31B
+3.1% YoY
3.91B
3.91B – 3.91B
+18.0% YoY
EBITDA
290.73M
est: 196.70M (+47.8%)
339.14M
est: 238.73M (+42.1%)
340.66M
est: 267.41M (+27.4%)
398.90M
est: 349.11M (+14.3%)
477.01M
est: 389.00M (+22.6%)
1.52B
est: 547.99M (+178.3%)
565.24M
est.
1.85B
est: 667.18M (+176.5%)
2.27B
est: 667.18M (+240.4%)
-549.97M
est: 38.92M (-1,513.2%)
38.92M
38.92M – 38.92M
+0.0% YoY
50.81M
50.81M – 50.81M
+30.6% YoY
56.61M
56.61M – 56.61M
+11.4% YoY
79.75M
79.75M – 79.75M
+40.9% YoY
82.26M
82.26M – 82.26M
+3.1% YoY
97.10M
97.10M – 97.10M
+18.0% YoY
EBIT
248.23M
est: 121.39M (+104.5%)
276.29M
est: 147.33M (+87.5%)
271.50M
est: 165.03M (+64.5%)
312.51M
est: 215.45M (+45.0%)
356.40M
est: 240.07M (+48.5%)
1.39B
est: 338.19M (+311.3%)
348.83M
est.
1.72B
est: 411.75M (+317.0%)
2.11B
est: 411.75M (+411.3%)
-788.79M
est: -86.14M (-815.7%)
-86.14M
-86.14M – -86.14M
+0.0% YoY
-112.46M
-112.46M – -112.46M
-30.6% YoY
-125.31M
-125.31M – -125.31M
-11.4% YoY
-176.52M
-176.52M – -176.52M
-40.9% YoY
-182.08M
-182.08M – -182.08M
-3.1% YoY
-214.92M
-214.92M – -214.92M
-18.0% YoY
Net Income
210.62M
est: 232.31M (-9.3%)
232.40M
est: 236.57M (-1.8%)
217.76M
est: 233.99M (-6.9%)
207.78M
est: 232.92M (-10.8%)
202.48M
est: 209.95M (-3.6%)
675.36M
est: 313.06M (+115.7%)
292.86M
est.
850.41M
est: 353.45M (+140.6%)
971.56M
est: 353.45M (+174.9%)
-732.14M
est: 238.42M (-407.1%)
238.42M
238.42M – 238.42M
+0.0% YoY
237.32M
237.32M – 237.32M
-0.5% YoY
213.92M
213.92M – 213.92M
-9.9% YoY
318.98M
318.98M – 318.98M
+49.1% YoY
298.40M
298.40M – 298.40M
-6.5% YoY
360.14M
360.14M – 360.14M
+20.7% YoY
SGA
268.65M
est: 165.11M (+62.7%)
320.29M
est: 200.40M (+59.8%)
351.52M
est: 224.47M (+56.6%)
489.17M
est: 293.05M (+66.9%)
642.83M
est: 326.53M (+96.9%)
835.53M
est: 459.99M (+81.6%)
474.47M
est.
809.79M
est: 560.04M (+44.6%)
1.26B
est: 560.04M (+124.6%)
302.28M
est: 416.61M (-27.4%)
416.61M
416.61M – 416.61M
+0.0% YoY
543.88M
543.88M – 543.88M
+30.6% YoY
606.03M
606.03M – 606.03M
+11.4% YoY
853.72M
853.72M – 853.72M
+40.9% YoY
880.59M
880.59M – 880.59M
+3.1% YoY
1.04B
1.04B – 1.04B
+18.0% YoY
EPS
0.42
est: 0.46 (-8.7%)
0.45
est: 0.47 (-4.0%)
0.42
est: 0.46 (-9.4%)
0.41
est: 0.46 (-11.1%)
0.39
est: 0.42 (-6.2%)
1.33
est: 0.62 (+114.5%)
0.58
est.
1.65
est: 0.70 (+135.7%)
1.89
est: 0.70 (+170.0%)
-1.42
est: 0.46 (-406.4%)
0.46
0.46 – 0.46
+0.0% YoY
0.46
0.46 – 0.46
-0.5% YoY
0.42
0.42 – 0.42
-9.9% YoY
0.62
0.62 – 0.62
+49.1% YoY
0.58
0.58 – 0.58
-6.5% YoY
0.70
0.70 – 0.70
+20.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-28 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-27 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-26 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-25 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-22 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-21 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-20 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-19 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-18 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-15 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-14 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-13 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-12 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-11 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-08 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-07 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-06 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-30 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-29 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-28 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-27 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-24 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-23 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-22 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-21 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-20 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-17 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-16 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-250.71M
OE per share TTM
-0.49
Owner's Yield
-8.99%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
21.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-398.6K
Shares Outstanding
514.35M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Baogang Miao Vice President & Non-Independent Director — male
Hongying Jin Vice President, Board Secretary & Non Independent Director — female
Jiaming Liang Vice President & Non-Independent Director — male
Lei Yu Accounting Supervisor — —
Ming Li Chairman & President — male
Shin Kang Hyuk Vice President — male
Xian Feng Zang Financial Director — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Specialties